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An evaluation of methods for the isolation
of nontuberculous mycobacteria from
patients with cystic fibrosis, bronchiectasis
and patients assessed for lung
transplantation
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Abstract
Background: RGM medium is an agar-based, selective culture medium designed for the isolation of nontuberculous
mycobacteria (NTM) from the sputum of patients with cystic fibrosis (CF). We evaluated RGM medium for the detection
of NTM in patients with CF (405 samples), bronchiectasis (323 samples) and other lung diseases necessitating lung
transplantation (274 samples).
Methods: In total, 1002 respiratory samples from 676 patients were included in the study. Direct culture on RGM medium,
with incubation at two temperatures (30 °C and 37 °C), was compared with conventional culture of decontaminated
samples for acid-fast bacilli (AFB) using both a solid medium (Löwenstein-Jensen medium) and a liquid medium (the
Mycobacterial Growth Indicator Tube; MGIT).
Results: For all three patient groups, significantly more isolates of NTM were recovered using RGM medium incubated at
30 °C than by any other method (sensitivity: 94.6% vs. 22.4% for conventional AFB culture; P< 0.0001). Significantly more
isolates of Mycobacterium abscessus complex were isolated on RGM at 30 °C than by AFB culture (sensitivity: 96.1% vs. 58.8%;
P< 0.0001). The recovery of Mycobacterium avium complex was also greater using RGM medium at 30 °C compared to AFB
culture (sensitivity: 83% vs. 70.2%), although this difference was not statistically significant and a combination of methods
was necessary for optimal recovery (P= 0.21).
Conclusions: In the largest study of RGM medium to date, we reaffirm its utility for isolation of NTM from patients with CF.
Furthermore; we show that it also provides an effective tool for culture of respiratory samples from patients with
bronchiectasis and other lung diseases.
Keywords: Nontuberculous mycobacteria, Mycobacterium abscessus complex, Mycobacterium avium complex, Cystic fibrosis,
Bronchiectasis, Lung transplantation, AFB culture
* Correspondence: John.Perry@nuth.nhs.uk
1Microbiology Department, Freeman Hospital, Newcastle upon Tyne NE7
7DN, UK
2Faculty of Health and Life Sciences, Northumbria University, Newcastle upon
Tyne, UK
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Stephenson et al. BMC Pulmonary Medicine           (2019) 19:19 
https://doi.org/10.1186/s12890-019-0781-2
Background
Nontuberculous mycobacteria (NTM) are recognized as
significant respiratory pathogens, particularly in individ-
uals with pre-existing lung disease, for example, patients
with cystic fibrosis (CF) [1]. In the largest studies of in-
dividuals with CF, the prevalence of NTM in sputum has
been estimated at 6–13% [2] and is reported to be in-
creasing [3–6]. The dominant pathogens among NTM
causing respiratory disease in CF include members of
the Mycobacterium abscessus complex (MABSC) and
Mycobacterium avium complex (MAC). Chronic infec-
tion with MABSC is particularly problematic in CF and
is associated with a significant decline in lung function
[7]. It can also be extremely difficult to eradicate due
largely to high levels of intrinsic antimicrobial resistance.
NTM are also important pathogens in patients with
non-CF bronchiectasis and their prevalence appears to
be similar to that found in CF, with one meta-analysis
reporting a prevalence of 9.3% [8], however most studies
show a clear dominance of MAC [9].
Reduced lung function associated with CF or other
lung pathologies may necessitate lung transplantation as
a treatment of last resort. However, infection with NTM
may complicate lung transplantation, with severe
post-operative infections frequently associated with
MABSC [10–13].
The isolation of NTM from the respiratory tract may re-
flect innocuous colonization or active infection character-
ized by progressive inflammatory lung damage [1].
NTM-pulmonary disease (NTM-PD) is defined by the
presence of specific microbiological, clinical and radio-
logical features [14]. Therefore, although isolation of
NTM by culture does not provide a diagnosis for
NTM-PD, culture remains a cornerstone of diagnosis [15].
The recommended procedure for isolation of NTM is
conventional acid-fast bacilli (AFB) culture that utilizes
methods originally designed for isolation of Mycobacter-
ium tuberculosis. These include the decontamination of
sputum samples (e.g. using alkali or acid) followed by cul-
ture for up to 8 weeks using both solid and liquid media.
One limitation is that the decontamination process is
known to reduce the viability of NTM thus reducing the
sensitivity of culture methods [1, 16, 17].
In 2016, Preece et al. reported the development of RGM
(“Rapidly-growing mycobacteria”) medium; a selective agar
that allows isolation of NTM without decontamination of
samples [18]. The medium was primarily designed for re-
covery of rapidly-growing mycobacteria (e.g. MABSC) and
consequently a 10-day incubation period was initially rec-
ommended. In a comparison with Burkholderia cepacia se-
lective agar, RGM medium showed a clear superiority for
recovery of NTM (sensitivity 98% vs. 31%; P < 0.0001) [18].
RGM medium subsequently showed equivalent sensitivity
to the Mycobacterial Growth Indicator Tube (MGIT), an
automated liquid culture system, for the detection of total
NTM from 187 patients with CF [19]. To accommodate
the isolation of MAC and other slow-growing species,
Plongla et al. extended the incubation of RGM to 28 days
and compared its performance to conventional methods
that included inoculation of MGIT plus Löwenstein-Jensen
medium (LJ). In an evaluation with 212 respiratory samples
from CF patients, a much higher yield of NTM was recov-
ered using RGM medium including a significantly higher
yield of MABSC [20].
The aim of this study was to compare 28-day culture on
RGM medium to conventional AFB culture using MGIT
and LJ with respiratory samples from three patient groups:
(1) patients with CF, (2) patients with non-CF bronchiec-
tasis (hereafter referred to as bronchiectasis; Br), and (3)
patients assessed for lung transplantation with a variety of
other lung diseases. It is well recognised that different spe-
cies of NTM have different temperature preferences and
that duplicate sets of media at two incubation tempera-
tures are frequently recommended for optimal recovery of
a wide range of species [14]. We therefore inoculated du-
plicate plates of RGM medium and compared incubation
at 30 °C with incubation at 37 °C.
Methods
Patient samples
A total of 1002 respiratory samples were routinely col-
lected from 676 patients for conventional AFB culture
over a 16-month period between April 2017 and July
2018. Samples were submitted at clinics dedicated to the
management of CF (n = 405) and Br (n = 323) or from
patients attending the cardiothoracic centre for lung
transplantation due to other lung diseases (n = 274). The
latter group were all assessed for lung transplantation
with most patients (91%) sampled pre-transplantation
and a minority of patients (9%) sampled in the
post-transplantation period. We cultured all consecu-
tively submitted samples from these patient groups with
no other selection criteria. Most samples were cultured
on the day of sample collection and the remainder after
storage for up to 48 h at 4 °C. A full description of the
samples and patients is available in Table 1.
Culture on RGM medium
Batches of RGM medium were prepared in-house as previ-
ously described [21]. All culture procedures were carried out
in a Class I safety cabinet. Samples were treated with an
equal volume of Sputasol (Oxoid; SR0233A) and then mixed
by vortexing at intervals until visibly homogeneous, except
for samples of broncho-alveolar lavage (BAL) that did not re-
quire homogenization. Aliquots of 100 μL were inoculated
onto two plates of RGM medium. Each plate was placed in a
sealed plastic bag and incubated for 28 days: one plate at
30 °C and one plate at 37 °C. Plates were examined for
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growth after 4 days, 7 days and then weekly. BAL samples
were centrifuged at 3000 rpm for 10min and the deposit
was re-suspended in 1mL of supernatant and cultured as
described above.
Any colonies recovered on RGM medium were sub-
jected to a Gram stain and a stain for AFB using the
auramine-phenol method. Non-mycobacteria were iden-
tified to species level using matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS, Bruker). Suspected mycobacteria
were also subjected to MALDI-TOF MS, following the
extraction protocol recommended by Bruker (the Myco-
bacteria Extraction (MycoEX) Method). Species identifi-
cation was achieved by matching spectra to those
available in the Bruker Mycobacteria Library version 4.0
(bead method). Any suspected strains of mycobacteria
that could not be identified using MALDI-TOF MS (or
required further sub-speciation e.g. for MAC) were re-
ferred to the National Mycobacterium Reference Service
in Birmingham, UK, for whole genome sequencing. Iso-
lates confirmed as MABSC by MALDI-TOF MS were
referred to the Antimicrobial Resistance and Healthcare
Associated Infections Reference Unit, Public Health
England, (PHE, Colindale, UK) for sub-speciation by se-
quencing of at least two of three housekeeping genes
(rpoB, hsp65 and sodA) as previously described [22].
AFB culture
The methods used were selected from those recom-
mended by Public Health England [23]. All procedures
Table 1 Summary of basic patient demographics and types of sample included in the study
All Cystic Fibrosis Bronchiectasis Other lung diseases*
No. of patients 676 279 239 158
Assessed for lung Tx 218 66 8 144
Post lung Tx 29 14 1 14
Mean age (years) 47 28 63 56
Age range (years) 2–91 2–77 9–91 13–72
% Male 48 52 38 56
% Female 52 48 62 44
No. of samples 1002 405 323 274
Sputum 969 401 312 256
BAL 22 3 4 15
Bronchial secretions 10 0 7 3
Tracheal aspirate 1 1 0 0
*Patients (n = 158) with other lung diseases included those with the following conditions:
n
Chronic obstructive pulmonary disease 51
Unspecified interstitial lung disease 28
Idiopathic pulmonary fibrosis 25
Fibrotic lung disease 22
Pulmonary hypertension 6
Sarcoidosis 6
Nonspecific interstitial pneumonia 5
Hypersensitivity pneumonitis 4
Lymphangioleiomyomatosis (LAM) 4
Complex congenital lung disease 1
Graft versus host disease 1
Histiocytosis X 1
Langerhans cell histiocytosis 1
Obliterative bronchiolitis 1
Pleuroparenchymal fibroelastosis (PPFE) 1
Progressive rheumatoid associated lung disease 1
Abbreviations: lung Tx lung transplantation, BAL broncho-alveolar lavage
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were carried out in a Class I safety cabinet within a cat-
egory 3 containment facility. Samples that had been ho-
mogenized with Sputasol (see above) were centrifuged at
3000 g for 15 min and the supernatant removed. A thin
smear of the deposit was used to prepare a slide for
staining using the auramine-phenol method and subse-
quent examination for AFB using fluorescence micros-
copy. All respiratory samples were subjected to
decontamination using the modified Petroff method
prior to culture for AFB. A 7mL aliquot of sodium hy-
droxide solution (4% w/v) was added to the centrifuged
deposit and vigorously mixed using a vortex mixer after
0, 5, 10, 15 and 20min. After a total of 25 min, the
sample was neutralised using 14 mL phosphate buffer
with pH indicator (final pH 6.8). The sample was
re-centrifuged and the deposit re-suspended in 2mL of
phosphate-buffered saline (PBS) at pH 6.8. A 0.5 mL
aliquot was then inoculated into a MGIT and loaded
onto the automated instrument for a minimum of 28
days incubation. A further 0.2 mL was inoculated onto a
pyruvate LJ slope and this was incubated for 8 weeks at
36 °C. For CF samples only, a further 0.2 mL was inocu-
lated onto a pyruvate LJ slope and this was incubated for
4 weeks at 30 °C. For certain samples, the incubation of
MGITs was extended to 56 days. This extended incuba-
tion was prompted by various factors including contam-
ination of LJ slope(s), previous history of mycobacterial
infection or a positive AFB smear.
For CF samples only, an additional round of decon-
tamination was carried out in parallel using half of the
original centrifuged deposit. An equal volume of sulfuric
acid (0.5 N) was added to the deposit, mixed by vortex-
ing and left for 60 min at ambient temperature. Approxi-
mately 20 mL of sterile distilled water was then added
and the sample centrifuged at 3000 g for 15 min. A 2mL
aliquot of PBS (pH 6.8) was then added to the deposit. A
0.5 mL aliquot was then inoculated into a MGIT and
loaded onto the automated instrument for a minimum
of 28 days incubation. Aliquots of 0.2 mL were then
taken for inoculation of two pyruvate LJ slopes (one in-
cubated at 30 °C for 4 weeks and one incubated at 36 °C
for 8 weeks). All of the culture methods are summarised
in Table 2.
For a positive MGIT, the entire content was decanted
into a sterile bottle and centrifuged at 3000 rpm for 15
min. The culture deposit was re-suspended in 1 ml PBS
with 4–6 glass beads, vortexed and left to settle for 5
min. A thin smear was then prepared for staining for
AFB and a chocolate agar plate was inoculated and incu-
bated in a sealed bag at 36 °C for 24 h. For samples yield-
ing non-mycobacteria, if the original sample was < 14
days old, the process of decontamination and culture in
a fresh MGIT was repeated. For samples not yielding
any microorganisms, the remainder of the deposit was
inoculated into fresh culture medium and the bottle
re-loaded on the MGIT instrument. LJ slopes were ex-
amined weekly and any colonies of suspect mycobacteria
were subjected to staining for AFB and also subcultured
on a chocolate agar plate as described above. Samples
that could be excluded as mycobacteria based on colony
characteristics and a negative AFB smear were not proc-
essed further. Suspect isolates of mycobacteria were re-
ferred to the National Mycobacterium Reference Service
in Birmingham, UK, for whole genome sequencing. Iso-
lates of M. abscessus complex were referred to PHE,
Colindale, UK, for sub-speciation as described above.
Any isolate of NTM that was only recovered by RGM
at one incubation temperature (or was only isolated
using AFB culture) was re-inoculated onto two plates of
RGM medium and two plates of RGM medium without
antibiotic supplement that were incubated at 30 °C and
37 °C for up to 28 days. This was performed by obtaining
a fresh culture of each strain on Middlebrook agar and
preparing a 0.5 McFarland suspension in sterile saline
Table 2 Summary of culture methods
Culture media Decontamination Inoculum Incubation Reading times
All samples RGM at 30 °C None 0.1 mL homogenized sample* 4 weeks 4,7,14,21,28 days
RGM at 37 °C None 0.1 mL homogenized sample* 4 weeks 4,7,14,21,28 days
CF samples MGIT H2SO4 0.5 mL of deposit. ≥ 4 weeks Continuous
MGIT NaOH 0.5 mL of deposit. ≥ 4 weeks Continuous
LJ at 30 °C H2SO4 0.2 mL of deposit. 4 weeks Weekly
LJ at 30 °C NaOH 0.2 mL of deposit. 4 weeks Weekly
LJ at 36 °C H2SO4 0.2 mL of deposit. 8 weeks Weekly
LJ at 36 °C NaOH 0.2 mL of deposit. 8 weeks Weekly
Non-CF samples MGIT NaOH 0.5 mL of deposit. ≥ 4 weeks Continuous
LJ at 36 °C NaOH 0.2 mL of deposit. 8 weeks Weekly
*Broncho-alveolar lavage (BAL) samples were concentrated by centrifugation prior to culture on RGM. Abbreviations: MGIT Mycobacterial Growth Indicator Tube,
LJ Löwenstein-Jensen medium, H2SO4; 0.5 N sulfuric acid, NaOH; 4% (w/v) sodium hydroxide
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(0.85%). A 1 μL aliquot was then spread onto each plate.
Information obtained from these subcultures was not
used in the calculation of specificity or sensitivity for the
various culture methods.
Statistical analysis
RGM culture at 30 °C was compared with RGM culture
at 37 °C using McNemar’s test with the continuity cor-
rection applied. Statistical significance was taken as P
< 0.05. The same method was used to compare RGM
culture at 30 °C with conventional AFB culture.
Results
Optimal temperature for incubation of RGM medium
Table 3 shows the numbers of NTM that were recovered
using RGM at two different temperatures. Significantly
more isolates of NTM were recovered on RGM medium
at 30 °C (n = 334) than at 37 °C (n = 79) (P < 0.0001).
This was mostly due to the isolation of species of doubt-
ful clinical significance (e.g. Mycobacterium gordonae)
that did not grow at 37 °C. However, for pathogenic spe-
cies known to be causes of lung infections, there was
also a greater yield at 30 °C. For example, the number of
isolates of MABSC was significantly higher at 30 °C than
at 37 °C (P = 0.016) and the yield of MAC was also
higher (P = 0.27).
For the few isolates of MABSC and MAC that were
only recovered at 37 °C, only 1–3 colonies were
recovered suggesting that the failure to recover these
isolates at 30 °C was most probably due to chance, rather
than a preference for a higher incubation temperature
(all isolates of MAC and MABSC grew well when
re-inoculated onto RGM and incubated at 30 °C). Over-
all, the data suggested little added benefit of using RGM
at 37 °C.
Comparison of culture using RGM medium at 30 °C with
conventional AFB culture
As we concluded that incubation of RGM medium at 37
°C offered little additional benefit, we then performed a
detailed comparison of the other two methods i.e. RGM
medium at 30 °C (“RGM 30 °C”) versus AFB culture.
Table 4 summarises all of the NTM isolated from 1002
respiratory samples and comparative data for these two
methods. A total of 353 isolates of NTM were recovered
using a combination of all methods and these were iso-
lated from 281 samples (i.e. 28% of samples yielded
NTM). A total of 57 samples (5.7%) contained more
than one species of NTM (with one specimen containing
as many as four distinct species). Mixtures of NTM spe-
cies were isolated from 50 samples by just using RGM
30 °C whereas only one mixture of NTM was detected
by just using AFB culture.
Of the 353 isolates, 334 (94.6%) were recovered on
RGM 30 °C compared with 79 (22.4%) recovered by AFB
culture (P < 0.0001). Notably, the sensitivity of RGM 30 °
C was significantly higher than AFB culture for detec-
tion of MABSC (sensitivity 96.1% vs. 58.8%; P < 0.0001).
The number of MAC isolates recovered on RGM was
also higher than the number recovered by AFB culture,
but this was not statistically significant (sensitivity 83%
vs. 70.2%; P = 0.21) and eight strains of MAC remained
undetected using RGM 30 °C. All of these eight strains
grew well when re-inoculated onto RGM and incubated
at 30 °C.
Acid-fast bacilli were observed by microscopy in only
24 respiratory samples (2.4%). For two of these samples,
no NTM (or any other type of AFB) were recovered by
any of the culture methods. The remaining 22
smear-positive samples were accounted for by growth of
MABSC (n = 12), MAC (n = 6) and single isolates of
Mycobacterium chelonae, M. gordonae, Mycobacterium
simiae and Mycobacterium species. All except the M.
simiae isolate were recovered on RGM 30 °C and all ex-
cept the single isolate of Mycobacterium species were re-
covered by AFB culture. M. tuberculosis is rarely
encountered in these patient groups in our centre, and
no strains of this species were recovered from any sam-
ples in this study.
In every patient group, large numbers of NTM belong-
ing to species other than MABSC and MAC were iso-
lated using RGM 30 °C and most of these remained
Table 3 Nontuberculous mycobacteria isolated from 1002
respiratory samples using RGM medium at two incubation
temperatures
Total
RGM
RGM RGM
30 °C 37 °C
M. chelonae complex 86 86 2
M. paragordonae / gordonae 56 56 0
M. llatzerense 52 52 0
M. abscessus complex (MABSC) 51 49 39
M. avium complex (MAC) 43 39 34
Mycobacterium species 27 26 1
M. mucogenicum-phocaicum group 8 8 0
M. septicum 6 6 0
M. fortuitum 2 2 1
M. lentiflavum 2 2 0
M. obuense 2 2 0
M. paraffinicum 2 2 0
M. arupense 1 1 0
M. mageritense 1 1 1
M. neoaurum 1 1 0
M. simiae 1 1 1
Total 341 334 79
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undetected using AFB culture. In most cases, these spe-
cies were isolated on RGM medium with very low
colony-counts. For example, M. llatzerense was isolated
from 52 samples but the mean colony count on RGM
30 °C was only 3.7 colonies, with only one colony of M.
llatzerense recovered from half of these 52 samples. In
contrast, the average colony count for MABSC was 67
on RGM 30 °C.
MABSC was detected in samples from 18 patients
using RGM 30 °C where AFB cultures were negative. In
10 of these patients (55%), the same subspecies was doc-
umented in at least one additional sample taken from
the same patient on a separate occasion. For seven pa-
tients, subsequent sputum cultures were negative when
cultures were repeated and for one patient repeat sam-
ples were not submitted. MAC was detected in samples
from 10 patients using RGM where AFB cultures were
negative. In seven of these patients (70%), the same sub-
species was documented in at least one additional sam-
ple taken from the same patient on a separate occasion.
For two patients, subsequent sputum cultures were
negative when cultures were repeated and for one pa-
tient repeat samples were not submitted.
The M. chelonae complex consists of M. chelonae and
three additional validated species; Mycobacterium frank-
linii, Mycobacterium immunogenum and Mycobacterium
salmoniphilum [24, 25]. M. chelonae complex was de-
tected in samples from 64 patients using RGM where
AFB cultures were negative. For 37 of these patients, re-
peat samples were cultured and M. chelonae complex
was recovered from 14 patients (38%).
When M. llatzerense or M. gordonae/paragordonae
were isolated, culture of repeat samples was much less
likely to yield the same species. For example, M. llatzer-
ense was detected in samples from 50 patients using RGM
where AFB cultures were negative. For 33 of these pa-
tients, repeat samples were cultured and M. llatzerense
was recovered from only three patients (9.1%). Similarly,
for M. gordonae/paragordonae only 2/31 patients (6.4%)
who had repeat cultures yielded the same species.
For 63/1002 specimens (6.3%), AFB cultures (both
solid and liquid media) were found to be overgrown by
Table 4 Nontuberculous mycobacteria recovered from 1002 respiratory samples from 676 patients by RGM at 30 °C and
conventional AFB culture
Totala RGM 30 °C AFB Culture RGM 30 °C AFB Culture
n n n Sensitivity (%)b Pb
M. abscessus complex (MABSC)c 51 49 30 96.1 58.8 < 0.0001
M. avium complex (MAC)d 47 39 33 83 70.2 0.21
M. chelonae complexe 86 86 4 100 4.7 < 0.0001
M. paragordonae / gordonae 57 56 3 98.2 5.3 < 0.0001
M. llatzerense 52 52 0 100 0 < 0.0001
Mycobacterium species 27 26 0 96.3 0 < 0.0001
M. mucogenicum-phocaicum group 8 8 0 – – –
M. septicum 6 6 0 – – –
M. simiae 5 1 5 – – –
M. fortuitum 2 2 1 – – –
M. lentiflavum 2 2 0 – – –
M. obuense 2 2 0 – – –
M. paraffinicum 2 2 0 – – –
M. arupense 1 1 0 – – –
M. iranicum 1 0 1 – – –
M. kumamotonense 1 0 1 – – –
M. mageritense 1 1 0 – – –
M. neoaurum 1 1 0 – – –
M. xenopi 1 0 1 – – –
Total 353 334 79 94.6 22.4 < 0.0001
aMABSC (n = 2), MAC (n = 3), and Mycobacterium sp. (n = 1) are included in the totals but were only isolated using RGM medium at 37 °C
bSensitivity and probability (P) were calculated only where the number of isolates (n) was > 10
cMABSC included subspecies abscessus (n = 30), subspecies massiliense (n = 13) and 8 isolates unresolved to subspecies level
dMAC included subspecies avium (n = 16), subspecies intracellulare-chimaera (n = 27) and M. colombiense (n = 1). 3 isolates could not be resolved further than M.
avium complex
eM. chelonae complex includes M. chelonae / salmoniphilum (n = 77) and M. franklinii (n = 9)
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species other than mycobacteria resulting in the prema-
ture termination of cultures, despite repeat attempts at
decontamination. This contamination rate was highest
for CF samples (14%) when compared with Br (1.2%)
and others (0.7%). In comparison, non-mycobacteria
were recovered from 11.2% of samples on RGM 30 °C
(21.4% for CF, 6.5% for Br and 1.5% for others). How-
ever, in the vast majority of cases, the growth of
non-mycobacteria on RGM plates was restricted and did
not compromise isolation of NTM. The most common
non-mycobacteria recovered on RGM 30 °C were
Gram-negative bacilli including Achromobacter species
and Burkholderia cepacia complex (data not shown).
The mean time to detection for NTM was similar for
AFB culture and RGM 30 °C, despite the fact that MGIT
was subjected to continuous monitoring and RGM was
only examined after 4 days and then weekly. For
MABSC, the mean time to detection was 5.5 days for
AFB culture (range: 2–21 days) and 6.1 days for RGM
30 °C (range: 4–28 days). For MAC the mean time to de-
tection was 14.6 days (range: 4–56 days) for AFB culture
and 15.2 days for RGM 30 °C (range: 4–28 days).
Cystic fibrosis group
MABSC was recovered from 35 specimens that were
submitted from 31 patients with CF indicating that
11.1% of patients with CF were infected or colonized by
MABSC. A total of 26 isolates of MAC were recovered
from 21 patients with CF (prevalence: 7.5%). The num-
ber of MABSC recovered from patients with CF was sig-
nificantly higher using RGM 30 °C [P = 0.004] with
almost one third of isolates undetected by AFB culture
(Table 5). Consequently, MABSC remained undetected
in 10 patients using AFB culture alone compared with a
failure to isolate MABSC in only one patient using RGM
30 °C. Both methods performed equally well for recovery
of MAC (P = 1.00). One isolate of Mycobacterium irani-
cum did not grow on RGM medium at either
temperature when re-inoculated as a pure strain and in-
cubated for 28 days.
Bronchiectasis group
A total of 15 isolates of MAC were recovered from spec-
imens submitted by 12 patients from the overall cohort
of 239 patients with Br giving a prevalence of 5%. Eight
isolates of MABSC were detected from seven patients
with Br (prevalence: 2.9%), with MABSC detected in 6/7
patients using RGM 30 °C and in only 1/7 patients using
AFB culture. As shown in Table 6, large numbers of
other NTM species were isolated using RGM 30 °C,
most of which were not recovered using AFB culture.
Other lung diseases
MABSC and MAC were isolated sporadically from pa-
tients with other lung conditions whose disease severity
had prompted an assessment for lung transplantation.
For example, MABSC was isolated from eight samples
(from five patients) using RGM 30 °C compared with
four samples (from 2 patients) using AFB culture. Each
of the five patients with MABSC had a different under-
lying lung disease. Six isolates of MAC were isolated
from samples collected from five patients, with MAC de-
tected in four patients using RGM 30 °C and two pa-
tients using AFB culture. Of the five patients with MAC,
Table 5 Nontuberculous mycobacteria recovered from 405 respiratory samples from 279 patients with cystic fibrosis
Totala RGM 30 °C AFB Culture RGM 30 °C AFB Culture
n n n Sensitivity (%)b Pb
M. abscessus complex (MABSC) 35 34 24 97.1 68.6 0.004
M. avium complex (MAC) 26 20 19 76.9 73.1 1.000
M. chelonae complex 22 22 2 100 9.1 < 0.0001
M. llatzerense 14 14 0 100 0 0.0005
M. paragordonae / gordonae 11 10 2 90.9 18.2 0.027
Mycobacterium species 11 10 0 90.9 0 0.004
M. mucogenicum-phocaicum group 3 3 0 – – –
M. paraffinicum 2 2 0 – – –
M. septicum 2 2 0 – – –
M. arupense 1 1 0 – – –
M. fortuitum 1 1 1 – – –
M. iranicum 1 0 1 – – –
M. obuense 1 1 0 – – –
Total 130 120 49 92.3 37.7 < 0.0001
aMABSC (n = 1), MAC (n = 2), and Mycobacterium sp. (n = 1) are included in the totals but were only isolated using RGM medium at 37 °C
bSensitivity and probability (P) were calculated only where the number of isolates (n) was > 10
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two had chronic obstructive pulmonary disease, two had
lymphangioleiomyomatosis (LAM) and one had
sarcoidosis.
As shown in Table 7, large numbers of other NTM
species were isolated using RGM 30 °C, most of which
were not recovered using AFB culture. However, occa-
sional strains could only be isolated using AFB culture.
For example, Mycobacterium simiae was recovered from
three separate sputum samples submitted from a patient
with idiopathic pulmonary fibrosis awaiting lung trans-
plantation. None of these isolates was recovered on
RGM medium and they did not grow on RGM medium
within 28 days when re-inoculated. M. simiae was suc-
cessfully recovered from a patient with Br in this study
and was isolated on RGM medium in a previous study
[21]. A strain of Mycobacterium xenopi was recovered
on LJ medium after 8 weeks of incubation at 36 °C but
was not recovered by RGM at either temperature (or
Table 6 Nontuberculous mycobacteria recovered from 323 respiratory samples from 239 patients with bronchiectasis
Total a RGM 30 °C AFB Culture RGM 30 °C AFB Culture
n n n Sensitivity (%)b Pb
M. abscessus complex (MABSC) 8 7 2 – – –
M. avium complex (MAC) 15 14 12 93.3 80 0.62
M. chelonae complex 32 32 0 100 0 < 0.0001
M. paragordonae / gordonae 32 32 1 100 3.1 < 0.0001
M. llatzerense 25 25 0 100 0 < 0.0001
Mycobacterium species 9 9 0 – – –
M. mucogenicum-phocaicum group 4 4 0 – – –
M. septicum 3 3 0 – – –
M. kumamotonense 1 0 1 – – –
M. lentiflavum 1 1 0 – – –
M. mageritense 1 1 0 – – –
M. neoaurum 1 1 0 – – –
M. simiae 2 1 2 – – –
Total 134 130 18 97 13.4 < 0.0001
aMABSC (n = 1) is included in the totals but was only isolated using RGM medium at 37 °C
bSensitivity and probability (P) were calculated only where the number of isolates (n) was > 10
Table 7 Nontuberculous mycobacteria recovered from 274 respiratory samples from 158 patients assessed for lung transplantation
with other respiratory diseases
Totala RGM 30 °C AFB Culture RGM 30 °C AFB Culture
n n n Sensitivity (%)b Pb
M. abscessus complex (MABSC) 8 8 4 – – –
M. avium complex (MAC) 6 5 2 – – –
M. chelonae complex 32 32 2 100 6.3 < 0.0001
M. paragordonae / gordonae 14 14 0 100 0 0.0005
M. llatzerense 13 13 0 100 0 0.0009
Mycobacterium species 7 7 0 – – –
M. simiae 3 0 3 – – –
M. fortuitum 1 1 0 – – –
M. lentiflavum 1 1 0 – – –
M. mucogenicum-phocaicum group 1 1 0 – – –
M. obuense 1 1 0 – – –
M. septicum 1 1 0 – – –
M. xenopi 1 0 1 – – –
Total 89 84 12 94.4 13.5 < 0.0001
aMAC (n = 1) is included in the total but was only isolated using RGM medium at 37 °C
bSensitivity and probability (P) were calculated only where the number of isolates (n) was > 10
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using MGIT). After re-inoculation, this isolate of M.
xenopi did not grow on RGM medium at 30 °C but grew
well on RGM medium after 21 days incubation at 37 °C.
Discussion
In 2016, the Cystic Fibrosis Foundation (CFF) and Euro-
pean Cystic Fibrosis Society (ECFS) published consensus
recommendations to support and standardise the manage-
ment of infections caused by NTM in children and adults
with CF [1]. The recommended methods to culture re-
spiratory samples for NTM are summarized in Table 8. At
the time these recommendations were compiled, in our
view, they appeared to reflect the best available evidence.
However, there are a number of drawbacks and/or limita-
tions to these recommendations, some of which are recog-
nized in the consensus document. For example, the
decontamination of respiratory samples is laborious and,
according to the recommendations, may substantially re-
duce the viability of mycobacteria, thereby reducing sensi-
tivity for detection of NTM [1]. The method is slow,
requiring at least 6 weeks before a negative result can be
issued (or longer if repeat rounds of decontamination are
required). Furthermore, contamination events cannot be
completely averted meaning that cultures may have to be
abandoned in some cases. In such cases, patients may
have to revisit the clinic to resubmit further sample(s). At
least two different types of culture media are required as
well as sophisticated instrumentation for automated mon-
itoring of liquid cultures. In many laboratories this means
that samples need to be processed in a separate location
to where routine culture for other bacterial pathogens is
performed. Perhaps mindful of the burden that these pro-
cedures place on clinical laboratories, routine screening
for NTM is only recommended on an annual basis. This
could be detrimental to the early detection of NTM
colonization / infection and might preclude opportunities
for early clinical management, particularly for MABSC.
For example, in a recent paper, Ravnholt et al. argue per-
suasively that the window of opportunity, before MABSC
transforms from a mucosal colonizer to a chronic biofilm
infection, is where microbial eradication is most likely to
be successful, making early diagnosis essential for im-
proved outcomes [26]. Delayed detection might also com-
promise efforts to limit patient-to-patient spread.
To address these limitations, the use of a highly selective
agar-based medium is an attractive option for isolation of
NTM, especially if it enables the culture of respiratory
samples without decontamination. A previous study from
Chapel Hill, United States, using 212 sputum samples
from patients with CF showed that culture using RGM
medium for 28 days at 30 °C recovered significantly higher
numbers of NTM and a much greater range of NTM spe-
cies, when compared to formal AFB culture [20]. In this
study, we have reproduced these findings with respect to
CF and we report similar findings for patients with Br and
various other lung diseases. In particular, we show a clear
advantage for RGM medium for the isolation of MABSC
(sensitivity 96.1% vs. 58.8%; P < 0.0001) and an equivalent
sensitivity of the two methods for the isolation of MAC
(sensitivity 83% vs. 70.2%; P = 0.21). In the United King-
dom, and elsewhere in Europe, MABSC is the dominant
pathogen among NTM in patients with CF [3, 4] and it
has been associated with a higher decline in lung function
than any other pathogen associated with CF lung disease
[7]. For this reason, we have adopted culture on RGM
medium as a first line screening test for all samples sub-
mitted from patients with CF. Conventional AFB culture
is reserved for patients with a strong clinical suspicion of
NTM disease, who have negative cultures using RGM.
MABSC is also an important pathogen in the context of
lung transplantation as it can cause serious post-operative
complications [10–13]. In a recent survey of transplant-
ation centres, 16 of 21 centres that responded to a ques-
tionnaire regarded persistent infection with MABSC as a
relative contraindication to lung transplantation [27]. A
higher number of respondents (18 of 21) required treat-
ment of such infections pre-transplantation [27]. The use
of RGM 30 °C was effective for isolation of MABSC from
patients awaiting lung transplantation with 8/8 isolates
successfully detected from five patients awaiting trans-
plantation. Only 4/8 isolates (from two patients) were de-
tected using AFB culture. In the case of Br, NTM is also
an important pathogen and screening is recommended if
there are clinical or radiological signs of disease, or if a pa-
tient is due to begin long term macrolide therapy [28].
MAC is generally regarded as the principal pathogen
among NTM affecting patients with Br [9]. We believe
that the data reported here for the use of RGM medium
Table 8 CFF / ECFS recommendations for microbiological
procedures for diagnosis of NTM lung disease in patients with
cystic fibrosis (CF) [1]
•Cultures for NTM should be performed annually in spontaneously
expectorating individuals with a stable clinical course.
•In the absence of clinical features suggestive of NTM pulmonary
disease, individuals who are not capable of spontaneously producing
sputum do not require screening cultures for NTM.
•Culture and smears for acid-fast bacilli from sputum should be used for
NTM screening.
•Oro-pharyngeal swabs should not be used for NTM screening.
•Cultures and smears for acid-fast bacilli from sputum, induced sputum,
bronchial washings or broncho-alveolar lavage samples can be used to
evaluate individuals with CF suspected to have NTM-pulmonary disease.
•Respiratory tract samples should be cultured using both solid and
liquid media and incubated for a minimum of six weeks.
•Respiratory tract samples should be decontaminated using N-acetyl L-
cysteine NALC (0.5%) - NaOH (2%).
•If a sample remains contaminated with Gram-negative bacteria after
standard decontamination, it should be further treated with either 5%
oxalic acid or 1% chlorhexidine.
•Non-culture based methods should not be used to detect NTM in
respiratory tract samples.
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for screening patients with Br justify further studies in dif-
ferent centres.
The fact that a far greater yield of NTM can be recov-
ered using RGM medium is remarkable when consider-
ing the relative inocula used for RGM medium and AFB
culture. A 100 μL aliquot of sputum diluted (1:1) in spu-
tasol is inoculated onto RGM medium compared with at
least 700 μL of a concentrated deposit that is used for
AFB culture. For a 10 mL sputum sample, the theoretical
inoculum is 70 x higher for AFB culture (or 180 x higher
for a CF sputum sample), assuming there are no losses
of NTM during the various centrifugation steps. This
provides convincing evidence of the deleterious effect of
decontamination on the viability of NTM.
AFB culture is generally able to detect NTM when
they are present at high inocula and, in such cases, per-
formance is equivalent to RGM. For example, when the
load of NTM was high enough in the sample to result in
a positive AFB smear, the sensitivity of the two methods
was identical. Furthermore, there was a very clear correl-
ation between the colony count obtained on RGM 30 °C
and the likelihood of detection of MABSC by AFB cul-
ture. For example, there were 16 specimens with a low
colony count (i.e. 1–10 colonies) of MABSC on RGM
30 °C and none of these was detected by AFB culture.
Conversely, there were 23 samples that produced a col-
ony count of > 50 MABSC and every one of these was
detected by AFB culture (see Fig. 1). A similar trend was
observed for MAC (data not shown).
Given that there is a clear association between the fail-
ure to detect NTM using AFB culture and lower num-
bers of NTM in these specimens, a major question
relates to the clinical significance of additional isolates of
NTM that are only detected using culture on RGM
medium. We do not yet have a clear answer to this
question. One of the first things to consider when asses-
sing the possibility of NTM-PD versus transient or per-
sistent colonization is whether the same species has
been recently isolated from the patient or whether it can
be isolated from a subsequent sample. If the presence of
NTM is sporadic, it is unlikely to signify NTM-PD. For
samples that are positive using RGM 30 °C but negative
by AFB culture, we have shown there is a good chance
that a repeat sample will give the same result for certain
species e.g. for MAC (70%), for MABSC (55%) and, to a
lesser extent, M. chelonae complex (38%). For other spe-
cies, such as M. llatzerense or M. gordonae/paragordo-
nae the number of colonies was typically very low and
the chances of isolating the same species from a repeat
sample was < 10%. In most if not all cases, the recovery
of such species that transiently colonize the respiratory
tract as commensals, or arise from environmental con-
tamination, may be regarded as more of a hindrance
than a benefit when using RGM medium.
Limitations of the study
Although the decontamination methods used in this
study for AFB culture are consistent with guidelines
Fig. 1 Correlation between colony count of MABSC on RGM at 30 °C and positive AFB culture (red bars) or negative AFB culture (blue bars)
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published in the United Kingdom [23], they are not con-
sistent with the most recent guidelines published by CF
societies in 2016 [1]. Furthermore, although all samples
were cultured on Löwenstein-Jensen medium for 8
weeks, the duration of incubation of MGIT vials for cul-
ture of NTM was typically restricted to 4 weeks due to
limitations in the capacity of the MGIT instrument. Al-
though previous studies suggest that incubation of
MGIT beyond 4 weeks is very unlikely to increase the
yield of NTM [19, 20], we cannot preclude the possibil-
ity that more NTM would have been isolated by MGIT
if we had incubated all samples for 6 weeks as recom-
mended in the most recent guidelines [1]. Finally, the
identification methods used in this study did not gener-
ate bacterial names that are consistent with the taxo-
nomic changes to the genus Mycobacterium proposed
and validated in 2018 [29, 30]. The bacterial names that
were valid at the start of this study (in 2017) have been
retained for convenience. Consequently, the term ‘NTM’
used in this paper does not just include species of the
genus Mycobacterium but also species of Mycobacter-
oides (e.g. Mycobacteroides abscessus), Mycolicibacterium
(e.g. Mycolicibacterium llatzerense) and Mycolicibacter
(e.g. Mycolicibacter kumamotonensis).
Conclusions
RGM medium is more sensitive than AFB culture for
detection of NTM across multiple patient groups (P <
0.0001). RGM should be incubated at 30 °C as originally
recommended [18] and an additional plate at 37 °C of-
fers negligible benefit for detection of NTM. RGM also
offers a higher sensitivity than AFB culture for detection
of MABSC and this relates primarily to the inability of
AFB culture to detect low inocula of MABSC. RGM has
equivalent sensitivity to AFB culture for the detection of
MAC, but optimal detection of MAC can be achieved by
combining both methods. Most isolates of MABSC or
MAC that are not recovered by AFB culture are recov-
ered from previous or subsequent samples from the
same patient indicating a persistent colonisation or in-
fection. A negative consequence of using RGM medium
is the isolation of an abundance of species of doubtful
clinical significance (e.g. M.llatzerense or M. gordonae/
paragordonae), which mostly appear to represent con-
tamination or transient colonization of the respiratory
tract.
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